Eyenovia, Inc. Announces Proposed Public Offering

Core Viewpoint - Eyenovia, Inc. plans to offer and sell shares of its common stock in a best efforts offering, subject to market conditions, with no assurance on the completion or terms of the offering [1]. Group 1: Offering Details - The offering will be conducted by Eyenovia and is subject to market conditions, with no guarantee on the timing or size of the offering [1]. - The net proceeds from the offering will be used for commercialization activities for Mydcombi and clobetasol propionate, completing the CHAPERONE pediatric myopia clinical study, and for working capital, which may include repaying existing debt [2]. - Dawson James Securities, Inc. is the sole placement agent for the offering [2]. Group 2: Regulatory Information - The offering is made under a shelf registration statement on Form S-3, filed with the SEC on December 14, 2021, and declared effective on December 23, 2021 [3]. - A prospectus supplement and accompanying prospectus will be filed with the SEC, providing details about the offering [3]. Group 3: Company Overview - Eyenovia, Inc. is an ophthalmic technology company that commercializes Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension, and is developing the Optejet® device for pediatric progressive myopia [5].